Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

67
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
67
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

399
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
399
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

188
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
188
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

125
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
125
Drugs Acting on Autonomic Ganglia: Stimulants01:23

Drugs Acting on Autonomic Ganglia: Stimulants

1.3K

Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.3K
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

2.2K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heat shock factor 1 signaling: A novel pathway implicated in Rett syndrome pathophysiology.

The Journal of pharmacology and experimental therapeutics·2026
Same author

Discovery of VU6077564: A Selective M<sub>1</sub> Antagonist That Promotes Neurite Outgrowth in Adult Sensory Neurons.

ACS chemical neuroscience·2026
Same author

Molecular pharmacology of mGlu<sub>7/8</sub> heterodimers reveals unique properties of orthosteric agonists and positive allosteric modulators.

Molecular pharmacology·2026
Same author

Discovery of VU6066098: A Selective and CNS-Penetrant mGlu<sub>2</sub> NAM with Robust Antidepressant-, Antipsychotic-, and Procognitive-like Activity in Rodents.

ACS chemical neuroscience·2026
Same author

Therapeutic potential of metabotropic glutamate receptor 7 modulation in correcting cognitive deficits of schizophrenia.

Schizophrenia research·2026
Same author

Discovery of VU6053371/BI03738809: A First-in-Class Selective and CNS-Penetrant mGlu<sub>3</sub> Positive Allosteric Modulator (PAM) with Efficacy in a Preclinical Cognition Model.

ACS chemical neuroscience·2026

Related Experiment Video

Updated: Jul 1, 2025

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.6K

Novel pharmacological targets for GABAergic dysfunction in ADHD.

Anthony S Ferranti1, Deborah J Luessen1, Colleen M Niswender2

  • 1Department of Pharmacology, Vanderbilt University, Nashville, TN, 37232, USA; Warren Center for Neuroscience Drug Discovery, Nashville, TN, 37232, USA.

Neuropharmacology
|March 10, 2024
PubMed
Summary

Attention deficit/hyperactivity disorder (ADHD) involves imbalances in brain excitation and inhibition. GABAergic dysfunction is increasingly implicated, offering new therapeutic targets beyond traditional stimulants for ADHD treatment.

Keywords:
ADHDAnterior cingulate cortexAttention-deficit/hyperactivity disorderCortexGABAGPCRGlutamateInterneuronNeurodevelopmentPrefrontal cortexPsychiatrySynaptic plasticityTranslational

More Related Videos

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
10:02

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD

Published on: March 12, 2020

15.7K
Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors
07:51

Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors

Published on: November 14, 2014

17.4K

Related Experiment Videos

Last Updated: Jul 1, 2025

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.6K
Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
10:02

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD

Published on: March 12, 2020

15.7K
Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors
07:51

Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors

Published on: November 14, 2014

17.4K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Genetics

Background:

  • Attention deficit/hyperactivity disorder (ADHD) affects ~5% of the population, characterized by impulsivity, hyperactivity, and attention deficits.
  • Current stimulant treatments for ADHD target dopaminergic signaling but are ineffective for nearly one-third of patients and have unclear long-term side effects.
  • Emerging evidence suggests dysregulated excitatory/inhibitory (E/I) balance, particularly involving GABAergic signaling, plays a crucial role in ADHD pathophysiology.

Purpose of the Study:

  • To review the role of GABAergic dysfunction in ADHD pathophysiology.
  • To explore potential pharmacological targets within GABAergic interneuron pathways for ADHD treatment.
  • To discuss implications for subpopulations with specific comorbidities and symptom domains.

Main Methods:

  • Review of current clinical evidence and emerging research on E/I balance in ADHD.
  • Analysis of findings from genome-wide association studies (GWAS) linking GABA genes to ADHD.
  • Examination of genetic mouse models of ADHD related to GABAergic dysfunction.

Main Results:

  • Genetic studies and mouse models highlight mutations in GABA-related genes in ADHD populations.
  • GABAergic interneuron dysfunction is increasingly recognized as a key mechanism in ADHD.
  • Dysfunctional GABA signaling contributes to E/I imbalance observed in ADHD.

Conclusions:

  • GABAergic dysfunction is a significant factor underlying ADHD pathophysiology.
  • Targeting specific GABA receptors and proteins offers a promising therapeutic avenue for ADHD subpopulations.
  • This approach may provide alternative treatments for patients unresponsive to stimulants or with specific comorbidities.